SoniVie

SoniVie is an Israeli startup that operates in the medical technology sector. The company is focused on developing a novel treatment for pulmonary arterial hypertension (PAH), a progressive disease that affects nearly 80,000 patients in the US alone. The treatment, known as TIVUS (Therapeutic Intra-Vascular Ultrasound System), is an investigational intravascular treatment that can be performed as part of a routine right heart catheterization.

The current treatment for PAH primarily involves the use of drugs, which increases as the disease progresses. However, SoniVie's TIVUS offers a potential non-drug alternative. Early clinical studies have shown that TIVUS can delay disease progression in PAH patients, potentially providing a safer and more cost-effective treatment option.

SoniVie's business model revolves around the development and commercialization of the TIVUS system. The company generates revenue through the sale of its TIVUS system to healthcare providers, who then use the system to treat PAH patients.

Recently, SoniVie has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the TIVUS System for renal artery denervation for the treatment of resistant hypertension. This designation will expedite the development and review process of the TIVUS system, potentially bringing it to market faster.

In summary, SoniVie is a promising startup that is developing a novel, non-drug treatment for PAH. The company's TIVUS system has the potential to improve the lives of thousands of patients suffering from this progressive disease.

Keywords: SoniVie, TIVUS, pulmonary arterial hypertension, non-drug treatment, medical technology, FDA Breakthrough Device Designation, renal artery denervation, resistant hypertension, healthcare providers, disease progression.